Gilde Healthcare
en nl de
  • Portfolio
  • Team
  • News
  • About us
  • Contact

News 2021

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008

Follow @GildeHealthcare

Axonics® expands into stress urinary incontinence with the acquisition of Bulkamid®

March 1, 2021 – IRVINE, California US – Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, last week announced that…

Related to: Axonics Modulation Technologies

Ace Pharmaceuticals strengthens shareholders base

March 1, 2021 – Zeewolde, the Netherlands – Ace Pharmaceuticals (Ace), a specialized pharmaceutical company in medical need medicines, strengthens its shareholders base with the addition of Gilde Buy Out Partners and Gilde Healthcare. Founded in 1990 and based in Zeewolde, Ace focuses on the development,…

Related to: Ace Pharmaceuticals

LAVA Therapeutics Appoints Dr. Kapil Dhingra as Chairman of the Board of Directors in Advance of Lead Program Entering the Clinic

February 22, 2021 – Utrecht, The Netherlands and Philadelphia, USA – LAVA Therapeutics B.V., an early clinical-stage biotechnology company focused on applying its expertise in bispecific gamma-delta T cell engagers to transform cancer therapy, today announced the appointment of Dr. Kapil Dhingra as chairman…

Related to: Lava Therapeutics

Acacia Pharma (EURONEXT: ACPH) raises EUR 27 million for US launch

February 19, 2021 – Cambridge, UK and Indianapolis, US – Acacia Pharma (EURONEXT: ACPH), a commercial stage biopharmaceutical company focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatments such as surgery, invasive procedures, or…

Related to: Acacia Pharma

Nyxoah and Vanderbilt University enter exclusive licensing agreement

February 2, 2021 – Utrecht (The Netherlands) – Nyxoah SA (Euronext: NYXH) (“Nyxoah” or the “Company”), a health-technology company focused on the development and commercialization of innovative solutions and services to treat Obstructive Sleep Apnea (OSA), today announces the Company has signed an exclusive…

Related to: Nyxoah

Acacia Pharma launches BYFAVO™ in the United States for procedural sedation in adults undergoing medical procedures lasting 30 minutes or less

January 28, 2021 – Approximately 40 million procedures take place annually in the US that require the use of procedural sedation BYFAVO is the second Acacia Pharma product approved and launched in the US in the last year and extends its portfolio of new products targeting unmet needs in anesthesia Cambridge…

Related to: Acacia Pharma

Nyxoah announces full-body MRI compatibility for the Genio® system to treat Obstructive Sleep Apnea (OSA)

January 26, 2021 – Utecht (The Netherlands) – Nyxoah SA (Euronext: NYXH) (“Nyxoah” or the “Company”), a health-technology company focused on the development and commercialization of innovative solutions and services to treat Obstructive Sleep Apnea (OSA), today announces the Company has received CE…

Related to: Nyxoah

Acacia Pharma wins BEL Company of the Year for the second consecutive year

January 20, 2021 – This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. Cambridge (United Kingdom) and Utrecht (the Netherlands) – Acacia Pharma Group plc (EURONEXT: ACPH), a commercial stage biopharmaceutical company focused…

Related to: Acacia Pharma

RAD-x adds Radiologisches Zentrum Lahnstein (RZL) to its group

January 19, 2021 – Utrecht (the Netherlands) – RAD-x is welcoming Radiologisches Zentrum Lahnstein (“RZL”) in its group. Radiologisches Zentrum Lahnstein is a provider of diagnostic imaging services in the region Koblenz, Germany. Its three radiologists and almost 30 staff serve the community in…

Related to: RAD-x

AM-Pharma announces enrollment and financing of COVID-19 cohort in phase III REVIVAL trial

January 8, 2021 – First patients with COVID-19 enrolled in the REVIVAL Phase III study COVID-19 patients with sepsis-associated acute kidney injury will be included in an exploratory cohort in the pivotal trial enrolling up to 1,600 SA-AKI patients overall RVO, an agency of the Dutch Ministry of…

Related to: AM-Pharma

Gilde Healthcare leads $28 million financing in Volta Medical to revolutionize persistent AFib ablation

January 6, 2021 – Marseille (France) - Utrecht (the Netherlands) – Volta Medical, a French-based HealthTech startup, pioneering novel artificial intelligence (AI) algorithms to treat cardiac arrythmias, today announced that it has successfully raised an 28 million USD financing round led by Gilde Healthcare.…

Related to: Volta Medical

Gilde Healthcare

Gilde Healthcare

Gilde Healthcare is a specialized healthcare investor managing over €1.4 billion ($1.5 billion) across two fund strategies: venture & growth capital and private equity. Gilde Healthcare's venture & growth capital fund invests in health tech and therapeutics. The venture & growth companies are based in Europe and North America. Gilde Healthcare's private equity fund invests in profitable European lower mid-market healthcare companies with a focus on the Benelux and DACH region. The private equity fund targets healthcare providers, suppliers of medical products and service providers in the healthcare market.

Investment Philosophy

Gilde Healthcare invests in fast growing, innovative businesses delivering better care at lower cost.

  • Home
  • Portfolio
  • Team
  • News
  • Contact
  • Imprint
  • Privacy Policy
  • SFDR Disclosure